肝素治疗进展性脑血栓患者25例临床分析关键思路分析  

Analysis of the Key Ideas in the Clinical Analysis of 25 Patients with Progressive Cerebral Thrombosis Treated with Heparin

作　　者：关飞 GUAN Fei(Department of Neurology,People's Hospital of Jieshou City,Jieshou,Anhui Province,236502 China)

机构地区：[1]安徽省界首市人民医院神经内科,安徽界首236502

出　　处：《中外医疗》2021年第30期99-102,共4页China & Foreign Medical Treatment

摘　　要：目的探讨对进展性脑血栓患者应用低分子肝素辅助治疗,并分析其应用效果。方法随机选取2018年12月—2020年11月在该院治疗的50例进展性脑血栓患者,将其分为两组。对照组25例,采取常规治疗,同时使用丁苯酞氯化钠;观察组25例,在对照组基础上应用低分子肝素。对比两组患者的临床疗效、血流动力学指标、Hcy水平。结果观察组患者总有效率为96%,明显高于对照组的总有效率68%,差异有统计学意义(χ^(2)=4.878,P<0.05);治疗后,观察组患者WBV、PV、Fg水平(4.70±0.51)mPa·s、(1.48±0.23)mPa·s、(3.66±0.26)g/L,均明显低于对照组(5.38±0.54)mPa·s、(1.77±0.24)mPa·s、(3.96±0.22)g/L,差异有统计学意义(t=4.577、4.362、4.404,P<0.05);治疗后,观察组患者的Hcy水平(10.10±1.89)μmol/L明显低于对照组(14.26±2.02)μmol/L,差异有统计学意义(t=7.159,P<0.05);治疗后,观察组患者的NIHSS评分(7.67±2.12)分,明显低于对照组(13.85±2.33)分,ADL评分(84.85±6.97)分,明显高于对照组(71.77±6.56)分,差异有统计学意义(t=9.809、6.833,P<0.05)。结论应用低分子肝素辅助治疗进展性脑血栓能够更为显著地改善血流动力学、Hcy水平及日常生活能力,提高整体疗效,明显优于单用丁苯酞,更具应用价值。Objective To explore the application of low molecular weight heparin in the adjuvant treatment of patients with progressive cerebral thrombosis,and analyze its application effect.Methods 50 patients with progressive cerebral thrombosis treated in the hospital from December 2018 to November 2020 were randomly selected and divided into two groups.The 25 cases in the control group received conventional treatment and butylphthalide sodium chloride at the same time.In the observation group,25 cases were treated with low molecular weight heparin on the basis of the control group.The clinical efficacy,hemodynamic indexes,and Hcy levels of the two groups of patients were compared.Results The total effective rate of observation group was 96%,which was significantly higher than that of control group(68%),the difference was statistically significant(χ^(2)=4.878,P<0.05).After treatment,The WBV,PV and Fg levels in observation group(4.70±0.51)mPa·s,(1.48±0.23)mPa·s,(3.66±0.26)g/L were significantly lower than those in control group(5.38±0.54)mPa·s,(1.77±0.24)mPa·s,(3.96±0.22)g/L,the difference was statistically significant(t=4.577,4.362,4.404,P<0.05).The Hcy level in observation group(10.10±1.89)μmol/L was significantly lower than that in control group(14.26±2.02)μmol/L,the difference was statistically significant(t=7.159,P<0.05).After treatment,NIHSS score of observation group(7.67±2.12)points was significantly lower than that of control group(13.85±2.33)points,and ADL score(84.85±6.97)points was significantly higher than that of control group(71.77±6.56)points,the difference was statistically significant(t=9.809,6.833,P<0.05).Conclusion Low molecular weight heparin can significantly improve hemodynamics,Hcy level and daily living ability in the adjuvant treatment of progressive cerebral thrombosis,improve the overall efficacy,which is significantly better than butylphthalide alone and has more application value.

关 键 词：进展性脑血栓 低分子肝素 血流动力学 同型半胱氨酸 

分 类 号：R743.32[医药卫生—神经病学与精神病学]